The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

Fitzal, F; Filipits, M; Rudas, M; Greil, R; Dietze, O; Samonigg, H; Lax, S; Herz, W; Dubsky, P; Bartsch, R; Kronenwett, R; Gnant, M
April 2015
British Journal of Cancer;4/14/2015, Vol. 112 Issue 8, p1405
Academic Journal
Background:The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence (LR)-free survival (LRFS) following surgery for breast cancer in postmenopausal women. In addition, we examined whether EP may help tailor local therapy in these patients.Methods:From January 1996 to June 2004, 3714 postmenopausal patients were randomly assigned to either tamoxifen or tamoxifen followed by anastrozole within the prospective ABCSG 8 trial. Using assay scores from EP, we classified breast tumour blocks as either low or high risk for recurrence.Results:Data were gathered from 1324 patients. The median follow-up was 72.3 months and the cumulative incidence of LR was 2.6% (0.4% per year). The risk of LR over a 10-year period among patients with high-risk lesions (n=683) was significantly higher (LRFS=91%) when compared with patients with low-risk lesions (n=641) (10-year LRFS=97.5%) (HR: 1.31 (1.16-1.48) P<0.005). The groups that received breast conservation surgery (BCT) and mastectomy (MX) had similar LR rates (P=0.879). Radiotherapy (RT) after BCT significantly improved LRFS in the cohorts predicted by EP to be low-risk for LR (received RT: n=436, 10-year LRFS 99.8%; did not receive RT: n=63, 10-year LRFS 83.6%, P<0.005).Conclusions:EndoPredict is an effective prognostic tool for predicting LRFS. Among postmenopausal, low-risk patients, EP does not appear to be useful for tailoring local therapy.


Related Articles

  • Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. Fitzal, Florian; Riedl, Otto; Wutzl, Lisa; Draxler, Wolfgang; Rudas, Margaretha; Pluschnig, Ursula; Handl-Zeller, Leonore; Dubsky, Peter; Bachleitner-Hofmann, Thomas; Steger, Günther; Jakesz, Raimund; Gnant, Michael // Breast Cancer Research & Treatment;May2007, Vol. 103 Issue 1, p45 

    Breast conservation therapy (BCT) increases quality of life and self-esteem of breast cancer patients. In special cancer centers up to 90% of patients are treated with BCT. T3/T4 breast cancer is one of the few contraindications for BCT. However, retrospective data suggest that BCT may be...

  • Therapeutic effects of cytoprotective agent on breast reconstruction after breast cancer surgery. Xinjia He; Lihua Wang; Wei Li; Zhuang Yu; Xingang Wang // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 11, p21925 

    Most patients will choose breast reconstruction after breast cancer surgery, while radiotherapy will damage skin and soft tissue so that will have adverse effect on reconstruction. In this study, we assume that the usage of Amifostine can reduce the incidence of complications after breast...

  • Radiotherapy may be unnecessary for older patients with breast cancer. Altersitz, Katrina // Hem/Onc Today;12/25/2013, Vol. 14 Issue 24, p16 

    The article reports on the PRIME II study which reveals that radiotherapy may not be necessary in treating older patients with hormone receptor-positive, axillary node-negative breast cancer.

  • Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. Quenel-Tueux, Nathalie; Debled, Marc; Rudewicz, Justine; MacGrogan, Gaetan; Pulido, Marina; Mauriac, Louis; Dalenc, Florence; Bachelot, Thomas; Lortal, Barbara; Breton-Callu, Christelle; Madranges, Nicolas; de Lara, Christine Tunon; Fournier, Marion; Bonnefoi, Hervé; Soueidan, Hayssam; Nikolski, Macha; Gros, Audrey; Daly, Catherine; Wood, Henry; Rabbitts, Pamela // British Journal of Cancer;8/11/2015, Vol. 113 Issue 4, p585 

    Background:The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to identify genomic changes occurring after...

  • Microdochectomy in the management of pathologic nipple discharge. Fajdić, Josip; Gotovac, Nikola; Glavić, Zeljko; Hrgović, Zlatko; Jonat, Walter; Schem, Christian // Archives of Gynecology & Obstetrics;Apr2011, Vol. 283 Issue 4, p851 

    Background: There is a debate in the literature whether a pathologic nipple discharge is a distinct sign of breast carcinoma. Our own results obtained by the use of microdochectomy as a minimally invasive operative procedure in 184 patients with pathologic nipple discharge were analysed. The aim...

  • Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Cella, David; Fallowfield, Lesley // Breast Cancer Research & Treatment;Jan2008, Vol. 107 Issue 2, p167 

    In postmenopausal women with hormone receptor-positive early-stage breast cancer, the use of aromatase inhibitors (AIs) to suppress estrogen is associated with improved clinical outcomes compared with tamoxifen therapy. Women receiving such endocrine therapy may experience treatment-related side...

  • Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Jisun Kim; Wonshik Han; Hyeong-Gon Moon; Soo Kyung Ahn; Hee-Chul Shin; Jee-Man You; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Hye Ryoung Koo; Jung Min Chang; Nariya Cho; Woo Kyung Moon; Dong-Young Noh // Breast Cancer Research;2012, Vol. 14 Issue 4, p1 

    Introduction: Anti-estrogen therapy has been shown to reduce mammographic breast density (MD). We hypothesized that a short-term change in breast density may be a surrogate biomarker predicting response to adjuvant endocrine therapy (ET) in breast cancer. Methods: We analyzed data for 1,065...

  • Breast cancer - patient choice of treatment: preliminary communication. Ashcroft, J. J.; Leinster, S. J.; Slade, P. D. // Journal of the Royal Society of Medicine;Jan1985, Vol. 78 Issue 1, p43 

    Forty patients who have undergone treatment for breast cancer (mastectomy or lumpectomy plus radiotherapy) were assessed, both preoperatively and at intervals up to one year following surgery, using tests of anxiety, depression, body satisfaction, marital adjustment, self-esteem, sociability and...

  • HEALTH DISPARITY: TIME DELAY IN THE TREATMENT OF BREAST CANCER IN LOUISIANA. Ferdaus, Riaz; Min Su Kim; Larson, James S. // Journal of Health & Human Services Administration;Dec2011, Vol. 34 Issue 3, p302 

    Previous studies have suggested that breast cancer patients with a delay of three months or more in initiating radiotherapy after breast conservative surgery, have increased recurrence and lower survival than those without treatment delay. In this study, the inequalities in receiving radiation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics